Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 24Neoplasm Metastasis 3Neoplasms by Site 2Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Breast Diseases 2Unilateral Breast Neoplasms 1Recurrence 1Osteitis Deformans 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HR+/HER2- Breast Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Breast Neoplasms, Male 1Anatomic Stage II Breast Cancer AJCC v8 1Advanced Metastatic Breast Cancer 1Advanced Breast Cancer 1

Interventions

Specimen Handling 2ribociclib 1exemestane 1durvalumab 1Taxes 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Drug Therapy 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anatomic Stage II Breast Cancer AJCC v8 × ribociclib × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡